# *In Silico* Molecular Docking against C-KIT Tyrosine Kinase of 2-Isoxazoline Derivatives

Shreyash D. Kadam<sup>1\*</sup>, Rutwa Bhatt<sup>1</sup>, Denni Mammen<sup>1</sup>, Laxmikant Nikam<sup>2</sup>

<sup>1</sup> School of Science, Navrachana University, Vasna-Bhayli Main Rd, Bhayli, Vadodara-391410, Gujarat, India <sup>2</sup> Gujarat Fluorochemicals Limited, Ranjitnagar, Gujarat-389380, India.

Received: 26 November 2022 Revised: 16 September 2023 Accepted: 28 December 2023 Published:29 December 2023

\*Corresponding Author: <u>kadamshreyash28@gmail.com</u>

https://doi.org/10.5281/zenodo.11560399

#### Abstract

2-Isoxazoline derivatives have been well known for their profound biological activities. A number of fluorinated derivatives with variable functional groups attached to the fivemembered heterocyclic ring have been synthesized and subjected to molecular docking studies, against C-KIT Tyrosine kinase target protein (1T46) in order to understand their binding properties and variations due to presence of fluorine atom. Molecular docking is a computer software-based study that is used to understand how a drug binds to a protein in the body. The interactions, binding, and affinity variations due to differences in functional groups have been studied using ChemDraw Ultra 7.0, RCSB – Protein Data Bank, BIOVIA Discovery Studio Visualizer 2021, MGL AutoDock Tools, AutoDock Vina and Vina Split software. The docking studies showed good interaction of the designed molecules with the 1T46 target protein.

# Keywords

2-Isoxazoline, Fluorine, Bioinformatics, Molecular Docking, C-KIT Tyrosine Kinase

#### Introduction

In the current era there is an increase in types of diseases, in addition to which new or existing viruses and bacteria are becoming resistant to drug molecules available in the market. For enhanced and effective protection against these diseases there is need for search of new moieties which can target these diseases and help to cure them. Molecular docking is an advantage since the structure of target provides a template for the discovery of novel ligands, which are different to those previously known.<sup>1</sup>

Nowadays structures of proteins and nucleic acids are easily accessible due to which the importance of molecular docking has been increased drastically. The molecular docking is a structure-based drug design method where the major focus is on protein-ligand interaction and provides prediction regarding the mode of binding and the affinity between receptors and ligands. In short, it is the study which displays how effectively the desired ligand fits into the pocket site of the target protein which is governed by the Lock-and-Key and Induced Fit theories for ligand binding. This type of computational technique is capable to improve the efficiency of drug and to reduce the research cost since by using the database the researchers are conveniently able to screen the potential pharmacophores by which they are able to purchase, synthesize and complete follow-up pharmacological tests. So molecular docking technique is widely used in drug design research. By performing docking studies researchers are being able to predict important properties such as, the drug-likeness, examine ligandprotein complex, binding energies, bond length, types of bond, as well as specificity of docking hits.<sup>2-5</sup> Molecular docking studies have gained immense support in the scientific world since it gives an idea regarding what types of molecules can act as potential drugs, without the use of animal models. These studies are used to save several animals such as mice, rats, rabbits and guinea pigs which have been used and sacrificed over the years in the name of scientific studies. These software studies may not be as accurate but do act as guiding forces towards the type of molecular structures the drugs need to possess to act to give the necessary healing actions.

Molecular docking analysis attempts to arrange molecules in favourable configurations via matching complementary features. This is a tricky task as there are numerous ways in which complex molecules can be linked.<sup>3-6</sup> Further, due to an exponential dependence on molecule size, numerous possible configurations are possible during docking involving biological macromolecules such as proteins or nucleic acid polymers, which adds to the difficulties.<sup>7-9</sup>

Currently the importance of small and highly electronegative fluorine atom in drug discovery and development is being realized. The selective addition of fluorine while synthesizing drug molecules can enhance several physicochemical and pharmacokinetic properties such as improved metabolic stability and enhanced membrane permeation. Increased binding affinity of fluorinated drug molecules to target protein has been recognized in various cases. After critical examination of the role of fluorine in medicinal chemistry it has been revealed that substitution of even a single fluorine atom or trifluoromethyl group in a key position of a biologically active organic compound imparts beneficial properties to that compound. At present, various fluorinated compounds are being synthesised regularly in pharmaceutical research which are widely used in the treatment of diseases such as anti-cancer agents, antidepressants, anti-inflammatory agents, anaesthetics and central nervous system drugs.<sup>10,11</sup>

Isoxazoline derivatives<sup>12-16</sup> are an important class of 5-membered oxygen and nitrogen containing heterocycles having profound biological properties. Also, from literature review it was found that this heterocycle could be a potent anticancer agent<sup>17-20</sup>. In addition to this, if these moieties contain fluorine or fluoroalkyl substituents it not only exhibits important pharmacological and agrochemical properties but also act as useful precursors for the synthesis of some biologically potent agents.<sup>21-24</sup> Due to this reason we have decided to perform structure-based ligand design on 2-Isoxazoline derivatives which target kinase protein. In this study we have performed molecular docking on designed moieties as ligand against C-kit tyrosine protein.

# **Experimental Section**

Targeting and suppressing specific protein kinases is gaining prominence as a novel therapeutic approach in the quest to combat cancer. STI-571 (imatinib, sold under the trade names Gleevec and Glivec) functions as a blocker of protein-tyrosine kinases within the Abl group. Imatinib is primarily used in the treatment of certain types of cancer, particularly chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). So, in our present selected protein STI was pre attached ligand and in this study, we are trying to check cancer potential for our synthesized structures, due to which we have used this protein and replaced STI with our synthesized structures. This was the reason we have selected this protein. Docking studies of all the 2-isoxazoline derivatives (**Figure 1**) were done via Discovery studio docking suite on target protein (PDB ID 1T46) (**Figure 2**).<sup>10</sup>

# Ligand preparation

We have synthesized structures with varied fluorine atoms to investigate the correlation between the number and positioning of fluorine<sup>25</sup> atoms within the moiety and compared there docking scores. Additionally, we explored the impact on docking by altering the positions of the trifluoromethyl group (ortho, meta, para). The structures of the 2-isoxazoline derivatives i.e. ligands (**Figure 1**) were drawn using Chemdraw Ultra 7.0 and saved in PDB format using Biovia Discovery Studio and the ligand was prepared by applying charges using MGL tools.<sup>10</sup>



Figure 1: Synthesized novel 2-isoxazoline derivatives

# Protein selection & Preparation

The X-ray crystal structure of kinase (PDB ID 1T46) (**Figure 2**) was obtained from pdb database and saved as pdb format for further studies. Selected protein macromolecule was prepared using Biovia Discovery Studio and charges were applied using MGL Tools.<sup>10</sup>



Figure 2: Structure of 1T46, C-KIT Tyrosine Kinase target protein used for Molecular Docking

The figure depicts the structure of the protein **1T46** on which molecular docking of all 10 2-Isoxazoline compounds have been performed.

# **Docking Studies**<sup>26</sup>

In this study, the affinity, and binding modes of the examined molecules against the target protein were determined. Firstly, water molecules were removed from the crystal structures of target proteins, retaining only main-chain amino acids which are essential for binding. The ligands were used as reference ligands to predict the binding pockets. Then, the polar hydrogen atoms were added to protein structures to protonate them. The structures of the examined compounds in PDB formats were opened using MGL AutoDock Tools software for preparation of protein which was selected as macromolecule and then saved in PDBQT format. The configuration file containing receptor name, ligand name, output file name, and X, Y, Z coordinates of the grid box were created. The ligand was prepared and any rotatable bonds if available were added. Next, in Command Prompt with the help of AutoDock Vina software docking process for each target receptor by ligand was carried out by entering necessary codes or commands.

In each case, 9 docked structural poses, affinity and RMSD data were generated using the algorithm. The output from the Vina split software was further analyzed and visualized with the help of BIOVIA Discovery Studio Visualizer 2021.<sup>10</sup>

# **Results and Discussion**

The synthesized 2-isoxazoline derivatives have been docked against kinase (PDB ID 1T46), the best compound was selected as per few criteria such as binding modes, good molecular interactions with the active site components of protein and docking energy at 0.00 RMSD

value. Docking scores and interacting amino acids were depicted in the **Table 1** below. Substituted 2-isoxazoline derivatives (**a-j**) have shown various Pi-Sigma, H-bonding, and halogen interactions towards 1T46 protein molecule. All the affinity values were observed to be within the range of -8.3 to -9.5 kcal/mol with favorable binding poses. One of the amino acids ASP810 in the 1T46 protein showed hydrogen bonding with almost all the compounds. Besides, two more amino acid CYS673 and ASP677 were also involved in H-bonding with various compounds. Among these compounds **h** and **i** exhibit strong interaction with active site amino acids with binding energy of -9.5 and -9.4 kcal/mol respectively towards 1T46 Kinase protein. This indicates that the presence of trifluoromethyl groups in in meta and para positions show the best affinity to the protein with maximum number of interactions. Fluorine atoms directly attached to the benzene rings show lesser interactions.

	Dealing		No of	Int	eraction Rea	No of	Bond	
Compounds	Energy	RMS	Interactions	Pi- Sigma	Halogen	H- Bonding	H Bonds	Length (Å)
Dovorubicin	77	0.00	0	VAL6		ASP810	2	2.6200 3
Doxorubiciii	-7.7	0.00	7	43	-	GLY812	2	2.9523 5
				LEU5		ASP810		2.1546
А	-8.3	0.00	10	95, LEU7 99, LEU7 99	-	UNK0	2	3.2806 6
D	-8.5	0.00	9	LEU5 95,		ASP810	2	2.1415 6
D		0.00		LEU7 99	-	UNK0		3.2581 8
C	-8.8	0.00	0	LEU5 95,	-	ASP810	2	2.1946 9
C		0.00	9	LEU7 99		UNK0	2	3.1813
D	-9.1	0.00	8	THR6 70	GLU640, GLU640	-	0	-
			12	LEU5		CYS673	3	2.1190 7
E	-9.0	0.00		95, LEU7	LEU595, CYS673	ASP810		2.1535 3
				99		UNK0		3.2956 6

				LEU5		CYS673		2.1607 2
f	-9.1	0.00	11	95, LEU7	CYS673	ASP810	3	2.2682 5
				99		UNK0		3.2406 1
G	-8.8	0.00	14	LYS6 23, THR6 70	GLU640, ASP810, ASP810, UNK0	ASP810	1	2.3568
			15	LEU5		LYS623		2.6006 8
Н	-9.5	0.00		95, LEU7 99	LEU595	ASP677	3	2.9607 5
						LYS623		3.3922 1
	-9.4	0.00	14	LEU7 99, LEU7 99	LEU595, GLY676	ASP677	3	2.8229 2
Ι						ASP810		2.2558 2
						UNK0		3.2381 2
						LYS623		2.9319 4
				LEU7	LEU595, LEU595,	CYS673		1.5837 5
J	-9.0	0.00	26	99, LEU7	GLU671, TYR672,	ASP677	5	2.8969 3
				99	TYR672, CYS673	ASP810		1.8606
						PHE811		3.5901 5

# Table 1: Docking scores and interactions of the analyzed molecules.

To visualize the interactions the 2D diagram and 3D interactions of compounds **h** and **i** are displayed below which have lowest affinity value -9.5 and -9.4 kcal/mol. (The colours of bond interactions is depicted in the table)



Figure 3: Molecular Docking 3D interaction output of 3-(3-Trifluoromethyl-phenyl)-4,5dihydro-isoxazole-5-carboxylic acid ethyl ester, h against 1T46 protein



Figure 4: Molecular Docking 2D interaction output of 3-(3-Trifluoromethyl-phenyl)-4,5dihydro-isoxazole-5-carboxylic acid ethyl ester, 7 against 1T46 protein

S		С	DIS						
r		OL	TA						
Ν		0	NC	CATE	TYPES OF	FRO			BON
0.	NAME	UR	Ε	GORY	BONDS	Μ	BONDS	ТО	DS
	A:LYS62					A:L		:U	
	3:HZ1 -		2.6	Hydrog		YS6		NK	H-
	:UNK0:O		006	en	Conventional	23:H		0:0	Accep
1	13		8	Bond	Hydrogen Bond	Z1	H-Donor	13	tor
	A:ASP67			Hydrog	Conventional	A:A	H-	:U	H-
	7:HN -		2.9	en	Hydrogen	SP67	Donor;H	NK	Accep
	:UNK0:F		607	Bond;H	Bond;Halogen	7:H	alogen	0:F	tor;Ha
2	20		5	alogen	(Fluorine)	Ν	Acceptor	20	logen



	A:LYS62				A:L		:U	
	3:CE -	3.3	Hydrog		YS6		NK	H-
	:UNK0:O	922	en	Carbon	23:C		0:O	Accep
3	14	1	Bond	Hydrogen Bond	E	H-Donor	14	tor
	A:LEU59						:U	
	5:O -	2.9			A:L		NK	
	:UNK0:F	121	Haloge	Halogen	EU5	Halogen	0:F	Halog
4	19	4	n	(Fluorine)	95:0	Acceptor	19	en
		· · ·		(110011110)	A·L			•
	A·I FI159	37			FU5		٠IJ	Pi-
	5°CD1 -	260	Hydron		95·C		NK	Orbita
5	JUNKO	200	hobic	Pi-Sigma	D1	C-H	0	10
5	.01110		nooic			<u>C-II</u>	U	15
	A.I E1170	38					• <b>T</b> T	Di
	A.LLU79	047	Undron				.U NV	11- Orbita
6	9.CD1 -	947	hobio	Di Ciama	99.C	CII		
0	ATVD67	56	noulc	r 1-Sigilia		С-П		15 D:
	A:IIKO/	J.0	Hudson			D:		ri-
7	2 -	804	Hydrop	D' D' C( 1 1	Y KO	P1-	INK	Orbita
/	:UNK0	1	hobic	P1-P1 Stacked	12	Orbitals	0	IS
	:UNK0:C							
	16 -				:UN		A:L	
	A:LYS62	4.2	Hydrop		K0:C		YS	
8	3	01	hobic	Alkyl	16	Alkyl	623	Alkyl
	:UNK0:C							
	16 -	5.0			:UN		A:L	
	A:LEU64	632	Hydrop		K0:C		EU	
9	4	1	hobic	Alkyl	16	Alkyl	644	Alkyl
	:UNK0:C						A:	
	16 -	4.1			:UN		VA	
1	A:VAL66	545	Hydrop		K0:C		L66	
0	8	3	hobic	Alkyl	16	Alkyl	8	Alkyl
	:UNK0:C							-
	17 -	4.0			:UN		A:L	
1	A:LEU59	081	Hydrop		K0:C		EU	
1	5	8	hobic	Alkyl	17	Alkyl	595	Alkyl
	:UNK0:C							
	17 -	5.2			:UN		A:L	
1	A:LEU79	630	Hydrop		K0.C		EU	
2	9	8	hobic	Alkyl	17	Alkvl	799	Alkvl
-	A·PHE81	0			- /		·U	
	1 -	53			Δ·Ρ		NK	
1	·UNK0·C	043	Hydrop		HF8	Pi-	0.0	
2	17	<del>د ا</del> ل	hobic	$\mathbf{D}_{1} \Delta 1 \mathbf{b} \mathbf{v} 1$	11	Orbitala	17	Albul
5	1/	0			11	Oronais	1/ Δ·	
	JINKO	1 1						
1	1.01NKU - 1.022	4.4	Hudson		JINI	D:		
	A:ALA62	139	Hydrop	D' A 11 1		11- 01:01	A0	A 11 1
4	1	6	nodic	P1-AIKYI	KU	Orbitals	21	AIKYI

							A:	
	:UNK0 -						CY	
1	A:CYS67	5.1	Hydrop		:UN	Pi-	S67	
5	3	215	hobic	Pi-Alkyl	K0	Orbitals	3	Alkyl

# Table 2: Total Number of Favorable Interactions: 15

The structure of 3-(3-Trifluoromethyl-phenyl)-4,5-dihydro-isoxazole-5-carboxylic acid ethyl ester as a ligand has been subjected to molecular docking with a protein molecule that would act as a receptor. Docking results exhibited 9 poses out of which the pose having the lowest affinity (kcal/mol) was selected as the best docking pose and so considered for the ligand interaction. Here, 15 favorable interactions **Table 2** were observed where the ligand has bonded at the chosen pocket site in the selected pose. The given table shows the information about the bonds between the ligand and amino acids which contains bond distance, types of bonds, from where the bond is forming and their types. The bonding interactions observed in this moiety while docking were -: three hydrogen bonds [conventional hydrogen bond, conventional hydrogen bond with fluorine and carbon hydrogen bond], one halogen bond [with fluorine] and eleven hydrophobic interactions [i.e. two pi-sigma, one pi-pi stacked, five alkyl and three pi-alkyl].



Figure 5: Molecular Docking 3D interaction output of 3-(4-Trifluoromethyl-phenyl)-4,5dihydro-isoxazole-5-carboxylic acid ethyl ester, i against 1T46 protein



Figure 6: Molecular Docking 2D interaction output of 3-(4-Trifluoromethyl-phenyl)-4,5dihydro-isoxazole-5-carboxylic acid ethyl ester, i against 1T46 protein

		C O							
S		L	DIS						
r		0	TA						
Ν		U	NC	CATE	TYPES OF	FRO			BON
0.	NAME	R	Ε	GORY	BONDS	Μ	BONDS	TO	DS
							H-		
	A:ASP67			Hydrog	Conventional	A:A	Donor;H		H-
	7:HN -		2.8	en	Hydrogen	SP67	alogen	:UN	Accep
	:UNK0:F		229	Bond;H	Bond;Halogen	7:H	Accepto	K0:F	tor;Ha
1	20		2	alogen	(Fluorine)	N	r	20	logen
	A:ASP81					A:A			
	0:HN -		2.2	Hydrog		SP81		:UN	H-
	:UNK0:O		558	en	Conventional	0:H		K0:	Accep
2	14		2	Bond	Hydrogen Bond	N	H-Donor	014	tor
	:UNK0:C							A:G	
	16 -		3.2	Hydrog		:UN		LU6	H-
	A:GLU6		381	en	Carbon	K0:		40:O	Accep
3	40:OE1		2	Bond	Hydrogen Bond	C16	H-Donor	E1	tor
	A:LEU59								
	5:O -		3.3			A:L	Halogen	:UN	
	:UNK0:F		729	Haloge	Halogen	EU5	Accepto	K0:F	Halog
4	18		4	n	(Fluorine)	95:O	r	18	en
	A:GLY6								
	76:C -		3.2			A:G	Halogen	:UN	
	:UNK0:F		979	Haloge	Halogen	LY6	Accepto	K0:F	Halog
5	20		8	n	(Fluorine)	76:C	r	20	en
	A:LEU79		3.7						Pi-
	9:CD1 -		469	Hydrop		A:L		:UN	Orbita
6	:UNK0		9	hobic	Pi-Sigma	EU7	C-H	K0	ls

					99:C			
					D1			
					A:L			
	A:LEU79				EU7			Pi-
	9:CD2 -	3.9	Hydrop		99:C		:UN	Orbita
7	:UNK0	615	hobic	Pi-Sigma	D2	C-H	K0	ls
	:UNK0:C							
	17 -	4.0			:UN		A:L	
	A:LYS62	604	Hydrop		K0:		YS6	
8	3	9	hobic	Alkyl	C17	Alkyl	23	Alkyl
	:UNK0:C							-
	17 -	5.4			:UN		A:L	
	A:LEU64	624	Hydrop		K0:		EU6	
9	4	5	hobic	Alkyl	C17	Alkyl	44	Alkyl
	:UNK0:C							
	17 -	4.1			:UN		A:V	
1	A:VAL6	100	Hydrop		K0:		AL6	
0	68	5	hobic	Alkyl	C17	Alkyl	68	Alkyl
	:UNK0:C							
	7 -	3.6			:UN		A:L	
1	A:LEU59	475	Hydrop		K0:		EU5	
1	5	6	hobic	Alkyl	C7	Alkyl	95	Alkyl
	:UNK0 -	4.5					A:L	
1	A:LEU59	938	Hydrop		:UN	Pi-	EU5	
2	5	9	hobic	Pi-Alkyl	K0	Orbitals	95	Alkyl
	:UNK0 -	4.9					A:V	
1	A:VAL6	171	Hydrop		:UN	Pi-	AL6	
3	03	9	hobic	Pi-Alkyl	K0	Orbitals	03	Alkyl
	:UNK0 -	4.5					A:A	
1	A:ALA6	465	Hydrop		:UN	Pi-	LA6	
4	21	2	hobic	Pi-Alkyl	K0	Orbitals	21	Alkyl

# Table 3: Total Number of Favourable Interactions: 14

In order to perform molecular docking analysis, the structure of 3-(4-Trifluoromethyl-phenyl)-4,5-dihydro-isoxazole-5-carboxylic acid ethyl ester has been selected as a ligand which is docked against protein molecule 1T46 acting as a receptor. During the analysis 9 different poses were observed, which was refined and the pose having lowest affinity (kcal/mol) was selected as the best docking pose and was considered for the ligand interaction. During this pose the ligand showed 14 favorable interactions in the chosen pocket site. **Table 3** provides information regarding bonding interaction between the ligand and amino acids in the protein chain which contains bond distance, types of bonds, from where the bond is forming and their types. The bonding interactions observed in this moiety while docking were three hydrogen bonds [conventional hydrogen bond, conventional hydrogen bond with fluorine and carbon hydrogen bond], two halogen bonds [with fluorine] and nine hydrophobic interactions [i.e. two pi-sigma, four alkyl and three pi-alkyl].

#### **Conclusion and Future directions**

The synthesized 2-isoxazoline derivatives have shown good interactions with the C-KIT Tyrosine Kinase (1T46) target protein, which indicates good anti-viral potential of the molecules. The presence of trifluoromethyl groups on the benzene ring show better interaction to the protein as compared to simple fluorine atoms directly attached to the benzene ring. This could give a proper direction to the synthetic organic chemist for synthesizing bio-active derivatives of 2-isoxazoline. In addition to this the *in-silico* analysis performed in this study will act as a base in future for conducting *in-vitro* analysis in the lab by carefully examining the computational data generated in this research article.

#### References

- Aarjane, M.; Slassi, S.; Ghaleb, A.; Tazi, B.; & Amine, A. Synthesis, biological evaluation, molecular docking and in silico ADMET screening studies of novel isoxazoline derivatives from acridone. *Arabian Journal of Chemistry*, 2021, *14*(4), 103057. https://doi.org/10.1016/j.arabjc.2021.103057
- Shoichet, B. K.; McGovern, S. L.; Wei, B.; Irwin, J. J. Lead discovery using molecular docking. *Current Opinion in Chemical Biology*, 2002, 6 (4), 439–446. https://doi.org/10.1016/s1367-5931(02)00339-3
- Kaur, P.; Arora, V., Significance of Molecular Docking in Developing Potent Antimicrobial 1,3,4-Thiadiazole Derivatives. *Letters in Organic Chemistry*, 2022, 19. https://doi.org/10.2174/1570178619666220930144853
- Noori, H. R.; Spanagel, R. In silico pharmacology: drug design and discovery's gate to the future. *In Silico Pharmacology*, 2013 1(1). https://doi.org/10.1186/2193-9616-1-1
- Lengauer, T., & Rarey, M. Computational methods for biomolecular docking. *Current Opinion in Structural Biology*, 1996, 6(3), 402–406. https://doi.org/10.1016/S0959-440X(96)80061-3
- 6. Taylor, R. D.; Jewsbury, P. J.; & Essex, J. W. A review of protein-small molecule docking

methods. *Journal of computer-aided molecular design*, 2002, *16*, 151-166. https://doi.org/10.1023/A:1020155510718

- Attique, S. A.; Hassan, M.; Usman, M.; Atif, R.; Mahboob, S.; Al-Ghanim, K. A.; Bilal, M.; Nawaz, M. A molecular docking approach to evaluate the pharmacological properties of natural and synthetic treatment candidates for use against hypertension. *International Journal of Environmental Research and Public Health*, 2019, *16*(6), 1–17. https://doi.org/10.3390/ijerph16060923
- Yuriev, E.; Ramsland, P. A. Latest developments in molecular docking: 2010-2011 in review. *Journal of Molecular Recognition*, 2013, 26(5), 215–239. https://doi.org/10.1002/jmr.2266
- 9. Yunta, M. J. R. Docking and Ligand Binding Affinity: Uses and Pitfalls. *American Journal of Modeling and Optimization*, 2016, 4(3), 74–114. https://doi.org/10.12691/ajmo-4-3-2
- Kadam, D.; Patil, S.; Mammen, D.; Kadam, S.; More, V. In Silico Molecular Docking Against C- KIT Tyrosine Kinase and ADME Studies of 4- Thiazolidinone Derivatives. J. Appl. Organomet. Chem, 2022, 3(1), 13–27. https://doi.org/https://doi.org/10.22034/jaoc.2023.355363.1058
- 11. Kadam, D.; Patil, S.; Kadam, S.; Doshi, A.; Patel, F. Synthesis of Novel 5-Arylidine-3-Ethyl-2-(2, 4, 5-Trifluorophenylimino)-Thiazolidin-One Derivatives Using Ultrasonic Knoevengel Conditions and Evaluation of Its Antimicrobial Activity. *Journal of Emerging Technologies and Innovative Research*, 2022, 9(8). https://doi.org/http://doi.one/10.1729/Journal.31452
- 12. Geetha, C. In vitro and molecular docking and analysis of isoxazoline derivatives with DPPH. *Bioinformation*, 2020, *16*(11), 807–816. https://doi.org/10.6026/97320630016807
- 13. Kumar, V.; & Kaur, K. Fluorinated isoxazolines and isoxazoles: A synthetic perspective. *Journal of Fluorine Chemistry*, 2015, 180, 55–97. https://doi.org/10.1016/j.jfluchem.2015.09.004
- 14. Shah, T.; Desai, V. Synthesis and antibacterial studies of some novel isoxazoline derivatives. *Journal of the Serbian Chemical Society*, 2007, 72(5), 443–449. https://doi.org/10.2298/jsc0705443s
- 15. Hatvate, N. T.; Ghodse, S. M. One-pot three-component synthesis of isoxazole using ZSM-5 as a heterogeneous catalyst. *Synthetic Communications*, 2020, 50(23), 3676–3683. https://doi.org/10.1080/00397911.2020.1815786

- Das, P.; Boone, S.; Mitra, D.; Turner, L.; Tandon, R.; Raucher, D.; Hamme, A. T. Synthesis and biological evaluation of fluoro-substituted spiro-isoxazolines as potential anti-viral and anti-cancer agents. *RSC Advances*, 2020, *10*(50), 30223–30237. https://doi.org/10.1039/d0ra06148d
- Arya, G. C.; Kaur, K.; Jaitak, V. Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies. *European journal of medicinal chemistry*, 2021, 221, 113511. https://doi.org/10.1016/j.ejmech.2021.113511
- Fawzi, M.; Bimoussa, A.; Laamari, Y.; Oussidi, A. N. A.; Oubella, A.; Ketatni, E. M.; Auhmani, A. New (S)-verbenone-isoxazoline-1, 3, 4-thiadiazole hybrids: synthesis, anticancer activity and apoptosis-inducing effect. *Future Medicinal Chemistry*, 2023, 15(17), 1603-1619. https://doi.org/10.4155/fmc-2023-0173
- Wazalwar, S. S., Banpurkar, A. R., & Perdih, F. Synthesis, crystal structure and molecular docking study of novel isoxazole derivatives as CYP450 inhibitors in search of anticancer agents. *Journal of Biomolecular Structure and Dynamics*, 2023, *41*(19), 9476-9491. https://doi.org/10.1080/07391102.2022.2142667
- 20. Lingam, J., Sahoo, B. K., Mallavarapu, B. D., & Sreenivasulu, R. Design, synthesis, anticancer evaluation and molecular docking studies of 1, 2, 4-oxadiazole incorporated indazole-isoxazole derivatives. *Synthetic Communications*, 2023, 1-12. https://doi.org/10.1080/00397911.2023.2282599
- 21. Aljohani, G. F.; El-Hag, F. A. A.; Bekheit, M. S.; Ewies, E. F.; El-Manawaty, M. A. An Efficient One-pot Synthesis of Certain Stereoselective Spiro[pyrazole-4,5'-isoxazoline]-5-one Derivatives: In vitro Evaluation of Antitumor Activities, Molecular Docking and in silico ADME Predictions. *Chemical Research in Chinese Universities*, 2022, 38(4), 1073–1082. https://doi.org/10.1007/s40242-022-1408-3
- 22. Oubella, A.; Byadi, S.; Bimoussa, A.; Fawzi, M.; Auhmani, A.; Podlipnik, C.; Morjani, H.; Riahi, A.; Robert, A.; & Itto, M. Y. A. Novel isoxazoline-linked 1,3,4-thiadiazole hybrids as anticancer agents: Design, synthesis, biological evaluation, molecular docking, and molecular dynamics simulation. *Archiv Der Pharmazie*, 2022, 355(9), 2200066. https://doi.org/10.1002/ardp.202200066
- Takenaka, K.; Nagano, T.; Takizawa, S.; Sasai, H. Asymmetric synthesis of chiral spiro bis(isoxazoline) and spiro (isoxazole–isoxazoline) ligands. *Tetrahedron: Asymmetry*, 2010, 21(4), 379–381. https://doi.org/10.1016/j.tetasy.2010.03.006

- 24. Fenton, C.; Keating, G. M.; Wagstaff, A. J. Valdecoxib. *Drugs*, 2004 64(11), 1231–1261. https://doi.org/10.2165/00003495-200464110-00006
- 25. Kadam, S. D.; Mammen, D.; Kadam, D. S.; Patil, S. G.; Bagul, R. R.; Doshi, A.; Patel, F. Synthesis of Novel Fluorinated 5-Benzylidine-3-ethyl-2-(2,3,4-trifluorophenylimino)thiazolidin-4-one Derivatives using Knoevenagel Reaction and Evaluation of their in vitro Antimicrobial Potentials. *Asian Journal of Chemistry*, 2023 35(8), 1884–1890. https://doi.org/https://doi.org/10.14233/ajchem.2023.28052
- 26. Kadam, S. D., Mammen, D., Kadam, D. S., & Patil, S. G. In silico molecular docking against C-KIT tyrosine kinase and ADME studies of 3-ethyl-2-(2, 3, 4-trifluorophenylimino)-thiazolidin-4-one derivatives. *Asian J. Research Chem*, 2023, *16*(1), 13–22. http://dx.doi.org/10.52711/0974-4150.2023.00010

#### Glossary

**2-Isoxazoline**- 2-Isoxazoline are nitrogen and oxygen containing five-membered heterocyclic scaffolds with extensive biological activities.

**Bioinformatics**- It is defined as the application of tools of computation and analysis to the capture and interpretation of biological data.

**Molecular Docking-** It is a process under category of bioinformatic modelling which involves the interaction of two or more molecules to give the stable adduct. Depending upon binding properties of ligand and target (protein), it predicts the three-dimensional structure of any complex.

**Protein ligand interactions**- Protein–ligand interactions are fundamental to almost all processes occurring in living organisms. This interaction occurs through the molecular mechanics involving the conformational changes among low affinity and high affinity states. Ligand binding interactions changes the protein state and protein function.

**Binding Site**- The region within a macromolecule i.e. protein that binds to another molecule with specificity. The binding partner of the macromolecule is often referred to as a ligand.

Binding affinity- It quantifies the binding strength of a ligand to a macromolecule i.e. protein.